amitriptyline hydrochloride(redirected from Apo-Amitriptyline)
Also found in: Dictionary, Thesaurus.
Apo-Amitriptyline, Levate (CA), Novotriptyn (CA)
Pharmacologic class: Tricyclic compound
Therapeutic class: Antidepressant
Pregnancy risk category D
FDA Box Warning
• Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk is greater during first few months of treatment, and must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.
• Drug isn't approved for use in pediatric patients.
Unclear. Inhibits norepinephrine and serotonin reuptake at presynaptic neuron, increasing levels of these neurotransmitters in brain. Also has sedative, anticholinergic, and mild peripheral vasodilating effects.
Tablets: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg
⊘Indications and dosages
➣ Depression (often given in conjunction with psychotherapy)
Adults: 75 mg P.O. daily in divided doses; may increase gradually to 150 mg/day. Or start with 50 to 100 mg P.O. at bedtime and increase by 25 to 50 mg as needed, to a total dosage of 150 mg. Hospitalized patients initially may receive 100 mg P.O. daily, with gradual increases as needed to a total dosage of 300 mg P.O.
• Elderly patients
• Analgesic adjunct for phantom limb pain or chronic pain
• Hypersensitivity to drug or other tricyclic antidepressants (TCAs)
• Acute recovery phase after myocardial infarction
• MAO inhibitor use within past 14 days
• Children younger than age 12
Use cautiously in:
• seizures, cardiovascular disease, renal or hepatic impairment, urinary retention, hyperthyroidism, increased intraocular pressure, closed-angle glaucoma, prostatic hypertrophy, bipolar disorder, schizophrenia, paranoia
• elderly patients
• pregnant or breastfeeding patients.
• Administer full dose at bedtime to minimize orthostatic hypotension.
• Don't withdraw drug suddenly. Instead, taper dosage gradually.
• If patient is scheduled for surgery, discuss dosage tapering with prescriber.
• Be aware that drug is often used in conjunction with psychotherapy.
CNS: headache, fatigue, agitation, numbness, paresthesia, peripheral neuropathy, weakness, restlessness, panic, anxiety, dizziness, drowsiness, difficulty speaking, excitement, hypomania, psychosis exacerbation, extrapyramidal effects, poor coordination, hallucinations, insomnia, nightmares, seizures, coma, suicidal behavior or ideation (especially in children and adolescents)
CV: ECG changes, tachycardia, hypertension, orthostatic hypotension, arrhythmias, heart block, myocardial infarction
EENT: blurred vision, dry eyes, mydriasis, abnormal visual accommodation, increased intraocular pressure, tinnitus
GI: nausea, vomiting, constipation, dry mouth, epigastric pain, anorexia, paralytic ileus
GU: urinary retention, delayed voiding, urinary tract dilation, gynecomastia
Hematologic: agranulocytosis, thrombocytopenia, thrombocytopenic purpura, leukopenia
Metabolic: changes in blood glucose level
Skin: photosensitivity rash, urticaria, flushing, diaphoresis
Other: increased appetite, weight gain, high fever, edema, hypersensitivity reaction
Drug-drug.Activated charcoal: decreased amitriptyline absorption
Adrenergics, anticholinergics, anticholinergic-like drugs: increased anti-cholinergic effects
Amiodarone, cimetidine, quinidine, ritonavir: increased amitriptyline effects
Barbiturates: decreased amitriptyline blood level, increased CNS and respiratory effects
Clonidine: hypertensive crisis
CNS depressants (including antihistamines, opioids, sedative-hypnotics): increased CNS depression
Drugs metabolized by CYP-4502D6 (such as other antidepressants, phenothiazines, carbamazepine, class 1C antiarrhythmics): decreased amitriptyline clearance, possibly causing toxicity
Guanethidine: antagonism of antihypertensive action
Levodopa: delayed or decreased levodopa absorption, hypertension
MAO inhibitors: hypotension, tachycardia, potentially fatal reactions
Rifabutin, rifampin, rifapentine: decreased amitriptyline blood level and effects
Selective serotonin reuptake inhibitors: increased risk of toxicity
Sympathomimetics: increased pressor effect of direct-acting sympathomimetics (epinephrine, norepinephrine), possibly causing arrhythmias; decreased pressor effect of indirect-acting sympathomimetics (ephedrine, metaraminol)
Drug-diagnostic tests.Eosinophils, liver function tests: increased values Glucose, granulocytes, platelets, white blood cells: increased or decreased levels
Drug-herbs.Angel's trumpet, jimson-weed, scopolia: increased anticholinergic effects
Chamomile, hops, kava, skullcap, valerian: increased CNS depression
St. John's wort: decreased drug blood level and reduced efficacy
Drug-behaviors.Alcohol use: increased CNS sedation
Smoking: increased drug metabolism and altered effects
Sun exposure: increased risk of photo-sensitivity reaction
• Evaluate for signs and symptoms of psychosis. If present, discuss possible dosage change with prescriber.
• Assess for changes in patient's mood or mental status.
☞ Monitor for signs and symptoms of depression and assess for suicidal ideation (especially in child or adolescent).
• Check blood pressure for orthostatic hypertension.
• Monitor CBC with white cell differential, glucose levels, and liver function test results.
☞ Instruct patient, parent, or care-giver to contact prescriber if severe mood changes or suicidal thoughts occur (especially if patient is child or adolescent).
• Tell patient that drug may cause temporary blood pressure decrease if he stands up suddenly. Advise him to rise slowly and carefully.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Inform patient that he'll undergo frequent blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.